Treatment of AA Amyloidosis

Nelson Leung, MD

Status and phase: Completed; Phase 1

Conditions: AA Amyloidosis

Treatments: Drug: nL-SAA1-01

Study type: Interventional

Funder types: Other

Identifiers

NCT06397001

22-005092

Details and patient eligibility

About

The purpose of this study is to assess the safety and efficacy of a subcutaneous injection of nL-SAA1-01in a patient with AA Amyloidosis.

Enrollment: 1 patient

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Biopsy proven AA amyloidosis
• Measurable disease
• Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records

Exclusion criteria

• Participant has any condition that in the opinion of the site investigator, would ultimately prevent the completion of study procedures

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

nL-SAA1-01

Experimental group

Description:

Subject will receive subcutaneous injection of nL-SAA1-01

Treatment:

Drug: nL-SAA1-01